Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

24-02-2022 | ASCO GU 2022 | Conference coverage | Video

Support for continuing enzalutamide after mCRPC progression

Axel Merseburger discusses the results of the PRESIDE trial of enzalutamide rechallenge in metastatic castration-resistant prostate cancer in the context of the current treatment landscape, and outlines unanswered questions (4:35).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

19-02-2020 | ASCO GU 2020 | Conference coverage | News

COSMIC-021: Cabozantinib–atezolizumab duo promising for mCRPC

30-09-2019 | Castration-resistant prostate cancer | Conference coverage | News

CARD results support cabazitaxel use in mCRPC

18-02-2022 | ASCO GU 2022 | Conference coverage | News

Early mCRPC promise shown for novel CYP11A1 inhibitor

16-02-2021 | ASCO GU 2021 | Conference coverage | News

Immunotherapy–docetaxel combinations show promise in mCRPC
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits